bit.bio

bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments.

bit.bio's opti-ox™ precision cell programming technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency.

bit.bio’s cell therapy pipeline, based on txCellsTM, is focused on serious diseases that lack effective treatments. The lead candidate, bbHEP01 based on txHepatocytes, is in development as a treatment for patients suffering from acute liver failure and acute-on-chronic liver failure.

The ioCells™ research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines in research and drug discovery.